Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solacy Adulte
- Development stage
- Unknown
- Lead developer
- Laboratoires Grimberg
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Solacy Adulte is an over-the-counter (OTC) fixed-dose combination drug developed by Laboratoires Grimberg for the symptomatic adjunctive treatment of nasopharyngeal disorders, such as chronic rhinopharyngitis, common colds, and rhinitis, in adults. The formulation combines L-cystine, precipitated sulfur, vitamin A (retinol), and Saccharomyces cerevisiae yeast. This combination is designed to reduce inflammation of the nasopharyngeal mucosa, promote tissue repair, and support local immune defenses. It is administered orally in the form of capsules.
- Brand names
- Solacy AdulteSolacy Adultes
- Other names
- L-cystine + retinol + Saccharomyces cerevisiae + sulfurSolacy
02
Targets
RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)
Beyond the preview
Go deeper on Solacy Adulte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solacy Adulte.